Ultime notizie per Cresco Labs (OTC:CRLBF) Azioni

Cresco Labs

Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and others. The company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.

Cresco Labs Inc

<p><strong>Landsea Homes</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Landsea Homes will report an <strong>earnings per share</strong> (EPS) of $-0.03. </p>
<p>Landsea Homes bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.22, leading to a 8.37% increase in the share price on the subsequent day.</p>
<p>Here's a look at Landsea Homes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.47</td>
<td>0.15</td>
<td>0.10</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.25</td>
<td>0.44</td>
<td>0.36</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821024_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Landsea Homes were trading at $6.1 as of May 08. Over the last 52-week period, shares are down 34.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LSEA/earnings"><strong>To track all earnings releases for Landsea Homes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

LSEA

An Overview of Landsea Homes's Earnings

<p><strong>Tango Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tango Therapeutics will report an <strong>earnings per share</strong> (EPS) of $-0.38. </p>
<p>Investors in Tango Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 5.05% drop in the share price the following trading session.</p>
<p>Here's a look at Tango Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.34</td>
<td>-0.37</td>
<td>-0.34</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.35</td>
<td>-0.27</td>
<td>-0.24</td>
<td>-0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-13.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821016_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Tango Therapeutics were trading at $1.1 as of May 08. Over the last 52-week period, shares are down 84.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Tango Therapeutics</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Tango Therapeutics.</p>
<p>Analysts have given Tango Therapeutics a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $13.0, indicating a potential 1081.82% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Tonix Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Tonix Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonix Pharmaceuticals</td>
<td>Outperform</td>
<td>-31.67%</td>
<td>$1.40M</td>
<td>-20.68%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tango Therapeutics ranks at the bottom among its peers in terms of consensus rating. It also lags behind in revenue growth and gross profit. Additionally, its return on equity is lower compared to its peers.</p>
<h3>Discovering Tango Therapeutics: A Closer Look</h3>
<p>Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.</p>
<h3>Financial Insights: Tango Therapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Tango Therapeutics faced challenges, resulting in a decline of approximately <strong>-24.19%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tango Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-914.99%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tango Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-17.57%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-11.26%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Tango Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.18</strong>.</p>
<p><a href="https://www.benzinga.com/quote/TNGX/earnings"><strong>To track all earnings releases for Tango Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TNGX

Insights into Tango Therapeutics's Upcoming Earnings

<p>Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Blink Charging will report an <strong>earnings per share</strong> (EPS) of $-0.12.</p>
<p>Blink Charging bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 5.99% increase in the share price on the following day.</p>
<p>Here's a look at Blink Charging's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.16</td>
<td>-0.16</td>
<td>-0.15</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.15</td>
<td>-0.16</td>
<td>-0.18</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-17.0%</td>
<td>-15.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820993_0.png" alt="eps graph" /></p>
<h3>Market Performance of Blink Charging's Stock</h3>
<p>Shares of Blink Charging were trading at $0.8366 as of May 08. Over the last 52-week period, shares are down 73.5%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BLNK/earnings"><strong>To track all earnings releases for Blink Charging visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BLNK

Insights into Blink Charging's Upcoming Earnings

<p><strong>Target Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) stock has slumped 29% so far this year, extending declines after falling in each of the last three years. The seventh biggest US retailer has seen a whopping two-thirds of its market value eroded since peaking just above $129 billion in mid-2021. Fast forward to 2025, and its market capitalization is just about $44 billion.</p>
<p>Target&#8217;s steep and extended declines in the stock market potentially serves as a <a href="https://www.benzinga.com/etfs">warning for ETF investors</a> who still think highly of big-box retail.</p>
<p><strong>What Does This Mean For ETFs?</strong></p>
<ul class="wp-block-list">
<li><strong>Retail ETFs: Risk In The Aisles</strong></li>
</ul>
<p>For funds invested in Target such as the <strong>VanEck Retail ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>), the retailer&#8217;s poor market performance has been a drag. A once-safe bet on middle-class spending, Target now embodies the agony of inflation-weary shoppers and the boundaries of retail automatization.</p>
<ol class="wp-block-list">
<li></li>
</ol>
<p>With peers such as <strong>Macy&#8217;s </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) also hinting at strain, these ETFs are as much at the mercy of changing U.S. consumer risks as ever.</p>
<ul class="wp-block-list">
<li><strong>Dividend ETFs: Is The Yield Worth The Risk?</strong></li>
</ul>
<p>Target continues to boast a 4.66% dividend yield, underpinned by a history of <a href="https://www.benzinga.com/quote/TGT/dividends">annual dividend increases</a>. That&#8217;s left it securely in the portfolio of <strong>VictoryShares Dividend Accelerator ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSDA#NASDAQ">VSDA</a>).</p>
<ol start="2" class="wp-block-list">
<li></li>
</ol>
<p>But be warned: Target&#8217;s dividend record may be strong, but without earnings growth or investor confidence, that won&#8217;t redeem the stock&#8217;s weakness.</p>
<p><strong>What&#8217;s Happening With TGT?</strong></p>
<ol start="3" class="wp-block-list">
<li></li>
</ol>
<p>In early 2025, when Target announced a rollback of its Diversity, Equity, and Inclusion (DEI) initiatives, it sparked criticism and a 40-day boycott by consumers. That pushed Target&#8217;s stock down further till it lost about $12.4 billion in market value by February.</p>
<p>Then came the class-action lawsuit following the backlash, which accused Target of misleading investors about the risks of changing its DEI policies. </p>
<p>It didn&#8217;t end there. That was followed by uncertainty over Target&#8217;s policy on self-checkout lanes. Media reports this week hinted that Target is limiting self-checkout to thwart shoplifting. But the company says it&#8217;s merely enforcing a 10-items-or-fewer rule—a policy it rolled out quietly in March 2024, not last weekend. But the confusion adds to the image of a company grappling to fill gaps while navigating turbulent macro seas.</p>
<p>Now, with customer worries about theft, &#8220;shrink,&#8221; and subpar customer experience, the sheen of tech-savvy retail is fading. A reminder that automation, poorly executed, can shrink more than products—it can lose consumer trust.</p>
<p>And now, amid fears that <a href="https://www.benzinga.com/news/global/25/04/45017240/covid-like-shortages-empty-shelves-expected-thanks-to-trump-tariffs-experts-say">U.S. tariffs on international trade will lead to empty shop shelves</a>, Target appears to be restocking investor anxiety more than customer baskets.</p>
<p>Adding more intrigue, Senator <strong>Shelley Moore Capito </strong>recently <a href="https://www.benzinga.com/insights/government/25/05/45290762/a-congress-member-sold-up-to-30k-in-target-stock-heres-what-you-need-to-know">sold TGT shares on May 7</a>, as reported under the STOCK Act. The range of value sold was $2,002 to $30,000. Although one congressional trade isn&#8217;t gospel, investors may consider this a subtle red flag.</p>
<p><strong>Final Receipt</strong></p>
<p>Target&#8217;s <a href="https://stockanalysis.com/stocks/tgt/market-cap/?utm_source=chatgpt.com">valuation </a>crash isn&#8217;t merely a corporate fall from favor—it might just be a flashing yellow warning light for ETF investors. If you&#8217;re in it for the dividends, sector exposure, or thematic play on retail disruption, it&#8217;s time to rethink what TGT does for your portfolio. As of today, this Target may be more of a moving one.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45319298/smart-hedged-and-contrarian-invescos-new-etfs-tackle-growth-risk-value-gaps">Smart, Hedged And Contrarian: Invesco&#8217;s New ETFs Tackle Growth, Risk, Value Gaps</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>



Equities

Sector ETFs

ETFs

Merrill Lynch Retail HOLDRS Trust due 12/31/41

VSDA

Target's Self-Checkout Flip-Flop Isn't Helping After A 66% Value Crash: Are Retail ETFs Ringing Up The Real Risk?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>D-Wave Quantum</strong>.</p>
<p>Looking at options history for D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) we detected 64 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 51 are puts, for a total amount of $2,138,942 and 13, calls, for a total amount of $674,235.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $8.0 to $15.0 for D-Wave Quantum during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for D-Wave Quantum options trades today is 3352.44 with a total volume of 204,657.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for D-Wave Quantum's big money trades within a strike price range of $8.0 to $15.0 over the last 30 days.</p>
<h3>D-Wave Quantum Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820978_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.75</td>
<td>$1.65</td>
<td>$1.66</td>
<td>$11.00</td>
<td>$697.2K</td>
<td>319</td>
<td>4.5K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$10.00</td>
<td>$112.0K</td>
<td>4.3K</td>
<td>435</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.4</td>
<td>$1.35</td>
<td>$1.35</td>
<td>$10.00</td>
<td>$81.0K</td>
<td>6.5K</td>
<td>3.1K</td>
</tr>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$1.25</td>
<td>$1.15</td>
<td>$1.2</td>
<td>$11.00</td>
<td>$60.0K</td>
<td>103</td>
<td>618</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$1.2</td>
<td>$1.1</td>
<td>$1.1</td>
<td>$10.00</td>
<td>$55.0K</td>
<td>5.2K</td>
<td>3.8K</td>
</tr>
</tbody>
</table>
</p>
<h3>About D-Wave Quantum</h3>
<p>D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.</p>
<p>Having examined the options trading patterns of D-Wave Quantum, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>D-Wave Quantum's Current Market Status</h3>
<ul>
<li>With a trading volume of 154,363,182, the price of QBTS is up by 6.7%, reaching $11.12.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>What Analysts Are Saying About D-Wave Quantum</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $13.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham persists with their Buy rating on D-Wave Quantum, maintaining a target price of $13. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for D-Wave Quantum, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

QBTS

This Is What Whales Are Betting On D-Wave Quantum

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Baidu</strong>.</p>
<p>Looking at options history for Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $146,961 and 5, calls, for a total amount of $336,366.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $120.0 for Baidu during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Baidu stands at 858.0, with a total volume reaching 1,387.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Baidu, situated within the strike price corridor from $70.0 to $120.0, throughout the last 30 days.</p>
<h3>Baidu Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820973_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$11.7</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$115.00</td>
<td>$136.8K</td>
<td>466</td>
<td align="right">120</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.9</td>
<td>$105.00</td>
<td>$95.8K</td>
<td>16</td>
<td align="right">652</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$2.71</td>
<td>$2.45</td>
<td>$2.52</td>
<td>$88.00</td>
<td>$43.5K</td>
<td>994</td>
<td align="right">228</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$5.05</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$90.00</td>
<td>$39.5K</td>
<td>137</td>
<td align="right">80</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.6</td>
<td>$7.55</td>
<td>$7.55</td>
<td>$85.00</td>
<td>$37.7K</td>
<td>1.3K</td>
<td align="right">98</td>
</tr>
</tbody>
</table>
</p>
<h3>About Baidu</h3>
<p>Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.</p>
<p>After a thorough review of the options trading surrounding Baidu, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Baidu Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,791,618, the BIDU's price is up by 0.01%, now at $87.66. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 12 days.</li>
</ul>
<h3>Professional Analyst Ratings for Baidu</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $90.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Baidu, which currently sits at a price target of $90. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Baidu with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


BIDU

What the Options Market Tells Us About Baidu

<p><strong>Quipt Home Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Quipt Home Medical will report an <strong>earnings per share</strong> (EPS) of $0.02. </p>
<p>Quipt Home Medical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.03, leading to a 2.32% drop in the share price the following trading session.</p>
<p>Here's a look at Quipt Home Medical's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0</td>
<td>0.01</td>
<td>-0.01</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>-0.07</td>
<td>-0.04</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-15.0%</td>
<td>-18.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820972_0.png" alt="eps graph" /></p>
<h3>Quipt Home Medical Share Price Analysis</h3>
<p>Shares of Quipt Home Medical were trading at $2.14 as of May 08. Over the last 52-week period, shares are down 46.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/QIPT/earnings"><strong>To track all earnings releases for Quipt Home Medical visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QIPT

Quipt Home Medical Earnings Preview

<p>Financial giants have made a conspicuous bullish move on Rocket Lab USA. Our analysis of options history for Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) revealed 18 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $74,000, and 16 were calls, valued at $850,083.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $30.0 for Rocket Lab USA over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Rocket Lab USA options trades today is 3249.57 with a total volume of 6,746.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Rocket Lab USA's big money trades within a strike price range of $3.0 to $30.0 over the last 30 days.</p>
<h3>Rocket Lab USA Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820968_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.78</td>
<td>$1.66</td>
<td>$1.66</td>
<td>$22.00</td>
<td>$132.8K</td>
<td>1.7K</td>
<td align="right">914</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.8</td>
<td>$12.35</td>
<td>$12.8</td>
<td>$10.00</td>
<td>$102.4K</td>
<td>12.5K</td>
<td align="right">80</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$2.9</td>
<td>$2.89</td>
<td>$2.9</td>
<td>$20.00</td>
<td>$98.8K</td>
<td>2.2K</td>
<td align="right">404</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.4</td>
<td>$6.3</td>
<td>$6.33</td>
<td>$20.00</td>
<td>$63.3K</td>
<td>8.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>RKLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.79</td>
<td>$2.73</td>
<td>$2.79</td>
<td>$20.00</td>
<td>$54.6K</td>
<td>5.1K</td>
<td align="right">578</td>
</tr>
</tbody>
</table>
</p>
<h3>About Rocket Lab USA</h3>
<p>Rocket Lab USA Inc is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, Germany, rest of the world and earns key revenue from the United States.</p>
<p>After a thorough review of the options trading surrounding Rocket Lab USA, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Rocket Lab USA Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 27,429,557, with RKLB's price down by -10.41%, positioned at $20.7.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Rocket Lab USA</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $28.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $28. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Rocket Lab USA, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


RKLB

Market Whales and Their Recent Bets on RKLB Options

<p>GAN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAN#NASDAQ">GAN</a>) reported quarterly losses of $(0.15) per share. This is a 66.67 percent decrease over losses of $(0.09) per share from the same period last year.  The company reported quarterly sales of $29.37 million which missed the analyst consensus estimate of $35.88 million by 18.16 percent.  This is a 4.19 percent decrease over sales of $30.65 million the same period last year.</p>


Earnings Misses

News

GAN Q1 EPS $(0.15) Down From $(0.09) YoY, Sales $29.37M Miss $35.88M Estimate

<p>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) has outperformed the market over the past 5 years by 10.15% on an annualized basis producing an average annual return of 24.66%. Currently, Sanmina has a market capitalization of $4.31 billion. </p>
<p><strong>Buying $1000 In SANM:</strong> If an investor had bought $1000 of SANM stock 5 years ago, it would be worth <strong>$2,874.60</strong> today based on a price of $80.54 for SANM at the time of writing.</p>
<h3>Sanmina's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820957_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

SANM

$1000 Invested In Sanmina 5 Years Ago Would Be Worth This Much Today

<p>WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) is preparing to release its quarterly earnings on Monday, 2025-05-12. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect WhiteHorse Finance to report an <strong>earnings per share</strong> (EPS) of $0.33.</p>
<p>Anticipation surrounds WhiteHorse Finance's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.06, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at WhiteHorse Finance's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.400</td>
<td>0.410</td>
<td>0.44</td>
<td>0.460</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.343</td>
<td>0.394</td>
<td>0.40</td>
<td>0.465</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-5.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820955_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of WhiteHorse Finance were trading at $9.31 as of May 08. Over the last 52-week period, shares are down 27.42%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WHF/earnings"><strong>To track all earnings releases for WhiteHorse Finance visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: WhiteHorse Finance's Earnings Preview

<p>A political action group trying to demonstrate its hatred of <strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and the company's CEO <strong>Elon Musk </strong>may have seen an experiment backfire into a sales pitch for the <a href="https://www.benzinga.com/news/23/12/36263412/watch-cybertruck-not-just-bulletproof-its-also-shopping-cart-proof-too-new-video-test-reveals">durability of the company's vehicles.</a></p>
<p><strong>What Happened</strong>: With Musk's increased role in politics in 2024 and 2025, <a href="https://www.benzinga.com/25/04/44963440/tesla-takedown-says-protests-are-working-hitting-ev-company-where-it-hurts-the-companys-bottom-line">protest groups have emerged </a>and targeted Tesla and other companies led by the world's richest man.</p>
<p>Led By Donkeys filmed a video of a Sherman tank taking on a Tesla Model 3, as reported by <a href="https://www.teslarati.com/anti-elon-musk-group-crushes-tesla-model-3-sherman-tank/">Teslarati</a>.</p>
<p>"We've crushed fascism before and we'll crush it again," World War II British army veteran <strong>Ken Turner</strong> said in the video.</p>
<p>The veteran said Musk is "using his immense power to support the far-right in Europe, and his money comes from Tesla cars."</p>
<p>The Model 3 in the video had a license plate reading "Fascism."</p>
<p>Watching the video footage shows the Model 3 held up well against the tank, with crushed windows and a crushed glass roof, but an overall surprisingly good body. The report said the vehicle looked liked the doors could still open despite being run over by a tank.</p>
<p>An M4 Sherman weighs between 66,800 to 84,000 pounds according to the report.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/interview/25/03/44539183/exclusive-tesla-protest-organizer-says-elon-musk-seems-to-have-purchased-the-american-government">EXCLUSIVE: Tesla Protest Organizer Says &#8216;Elon Musk Seems To Have Purchased The American Government&#8217;</a></strong></p>
<p><strong>Why It's Important</strong>: Tesla vehicles have become known for their durability over the years.</p>
<p>With plenty of protests against Tesla and Musk highlighting the CEO's political moves, this may not have been the right demonstration.</p>
<p>Vandalism to Tesla vehicles, which has increased in 2025, has also shown Tesla vehicles have some of the best cameras, helping with insurance claims.</p>
<p>Comments on social media about the video said a person inside the Model 3 may have been able to survive a tank running over their car.</p>
<p>In this battle of tank vs. Tesla, the round appears to have gone to Tesla.</p>
<p><strong>TSLA Price Action</strong>: Tesla stock is up 4.78% on Friday to $298.42 versus a 52-week trading range of $157.40 to $488.54. Tesla stock is down 21.6% year-to-date in 2025.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">Tesla Q1 Misses Estimates As Tariff Pressures Weigh On Outlook, Lower-Cost EVs Still On Track</a></strong></li>
</ul>
<p><em>Photo: Tesla Model 3, courtesy Tesla; Sherman tank at Utah Beach, Normandy, France, photo by Sonny Vermeer</em></p>


Entertainment

Education

TSLA

Tesla Defeats Tank? Anti-Musk Group's Experiment May Have Backfired Into A Sales Pitch

General

The Ontario Lottery And Gaming Corporation Selects Caesars Entertainment As The Service Provider In The Windsor Casino Procurement Process; This Is The Final Procurement Process In The OLG's Land-Based Gaming Modernization Initiative.

<p>ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.08) by 237.5 percent. This is a 88.89 percent increase over losses of $(2.43) per share from the same period last year.</p>


LOGC

ContextLogic Q1 EPS $(0.27) Misses $(0.08) Estimate

<p>12 analysts have shared their evaluations of Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $25.5, with a high estimate of $29.00 and a low estimate of $20.00. This current average has decreased by 7.0% from the previous average price target of $27.42. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820889_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Ingram Micro Holding by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ananda Barush</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ingram Micro Holding. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ingram Micro Holding compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Ingram Micro Holding's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Ingram Micro Holding's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Ingram Micro Holding analyst ratings.</strong></a></p>
<h2>About Ingram Micro Holding</h2>
<p>Ingram Micro Holding Corp is a technology company for the global information technology ecosystem. The company plays a vital role in the IT sales channel, bringing products and services from technology manufacturers and cloud providers to business-to-business technology experts. The company also provide a broad range of technology services, including financing, specialized marketing, and lifecycle management, as well as technical pre- and post-sales professional support.</p>
<h3>Breaking Down Ingram Micro Holding's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Ingram Micro Holding showcased positive performance, achieving a revenue growth rate of <strong>2.5%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>0.62%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.26%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ingram Micro Holding's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.45%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.02</strong>, Ingram Micro Holding faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

INGM

Where Ingram Micro Holding Stands With Analysts

<p>Throughout the last three months, 4 analysts have evaluated Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.25, a high estimate of $76.00, and a low estimate of $55.00. This upward trend is evident, with the current average reflecting a 4.92% increase from the previous average price target of $66.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820875_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Mirum Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Mirum Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Mirum Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Mirum Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MIRM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Mirum Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Mirum Pharmaceuticals</h2>
<p>Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.</p>
<h3>Understanding the Numbers: Mirum Pharmaceuticals's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Mirum Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>61.2%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Mirum Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-13.15%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Mirum Pharmaceuticals's ROE excels beyond industry benchmarks, reaching <strong>-6.4%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Mirum Pharmaceuticals's ROA excels beyond industry benchmarks, reaching <strong>-2.16%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Mirum Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at <strong>1.36</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MIRM

Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock

<p>Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Clarus and provided 12-month price targets. The average target is $5.25, accompanied by a high estimate of $7.00 and a low estimate of $4.00. Highlighting a 12.5% decrease, the current average has fallen from the previous average price target of $6.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820866_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Clarus by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Smith</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.50</td>
</tr>
<tr>
<td>Mark Smith</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clarus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Clarus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Clarus's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Clarus's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLAR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Clarus analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Clarus</h2>
<p>Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.</p>
<h3>A Deep Dive into Clarus's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Clarus faced challenges, resulting in a decline of approximately <strong>-6.66%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Clarus's net margin excels beyond industry benchmarks, reaching <strong>-91.76%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Clarus's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-24.2%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Clarus's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-19.58%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.07</strong>, Clarus adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CLAR

What Analysts Are Saying About Clarus Stock

<p><strong>Corcept Therapeutics's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NYSE">CORT</a>) short percent of float has fallen 25.63% since its last report. The company recently reported that it has <strong>12.29 million shares sold short</strong>, which is 16.31% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.11 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Corcept Therapeutics Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820856_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Corcept Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Corcept Therapeutics's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Corcept Therapeutics's peer group average for short interest as a percentage of float is 2.83%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

CORT

How Do Investors Really Feel About Corcept Therapeutics?

<p>Across the recent three months, 6 analysts have shared their insights on Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Globus Medical, revealing an average target of $88.67, a high estimate of $103.00, and a low estimate of $80.00. A decline of 4.83% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820853_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Globus Medical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Globus Medical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Globus Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GMED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Globus Medical analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Globus Medical</h2>
<p>Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.</p>
<h3>Globus Medical: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Globus Medical's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>6.61%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Globus Medical's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>4.03%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.64%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Globus Medical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.51%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.13</strong>, Globus Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GMED

A Glimpse Into The Expert Outlook On Globus Medical Through 6 Analysts

<p><strong>Charter Communications's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NYSE">CHTR</a>) short percent of float has fallen 8.18% since its last report. The company recently reported that it has <strong>11.26 million shares sold short</strong>, which is 11.78% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 7.23 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Charter Communications Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746820850_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Charter Communications has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Charter Communications's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Charter Communications's peer group average for short interest as a percentage of float is 9.05%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Comments

Cresco Labs

Notizie

Ultime notizie per Cresco Labs (OTC:CRLBF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO